Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
08/08/2023 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 1.5M | $14.39 | $21.6M | See footnotes | 08/08/2023 |
06/15/2023 | Nuvalent, Inc. | | Grant | Stock Option (Right to Buy) | 15k | $44.68 | $670.2k | | 06/15/2023 |
06/14/2023 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 500k | $12.68 | $6.3M | See footnotes | 06/14/2023 |
06/08/2023 | Mersana Therapeutics, Inc. | MRSN | Grant | Common Stock | 14.5k | $0.00 | $0 | | 06/08/2023 |
06/08/2023 | Mersana Therapeutics, Inc. | MRSN | Grant | Stock Option (right to buy) | 18.4k | $8.64 | $158.6k | | 06/08/2023 |
05/26/2023 | DYNAVAX TECHNOLOGIES CORP | DVAX | Grant | Common Stock | 5.4k | $0.00 | $0 | | 05/26/2023 |
05/26/2023 | DYNAVAX TECHNOLOGIES CORP | DVAX | Grant | Stock Option (Right to Buy) | 22.5k | $11.20 | $252k | | 05/26/2023 |
05/18/2023 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 1000k | $10.55 | $10.6M | See footnotes | 05/18/2023 |
12/06/2022 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 1.5M | $11.60 | $17.4M | See footnotes | 12/06/2022 |
11/03/2022 | Nuvalent, Inc. | | Purchase | Class A Common Stock | 149.3k | $33.50 | $5M | See footnotes | 11/03/2022 |
08/15/2022 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 3M | $14.68 | $44M | See footnotes | 08/15/2022 |
06/16/2022 | Nuvalent, Inc. | | Grant | Stock Option (Right to Buy) | 20k | $9.36 | $187.2k | | 06/16/2022 |
06/09/2022 | Mersana Therapeutics, Inc. | MRSN | Grant | Stock Option (right to buy) | 45k | $3.62 | $162.9k | | 06/09/2022 |
06/02/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 14.8k | $3.20 | $47.2k | See footnotes | 05/31/2022 |
05/31/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 80.8k | $3.28 | $264.8k | See footnotes | 05/31/2022 |
05/26/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 75k | $3.19 | $238.9k | See footnotes | 05/24/2022 |
05/26/2022 | DYNAVAX TECHNOLOGIES CORP | DVAX | Grant | Restricted Stock Unit | 5.4k | $0.00 | $0 | | 05/26/2022 |
05/26/2022 | DYNAVAX TECHNOLOGIES CORP | DVAX | Grant | Option (Right to Buy) | 22.5k | $11.68 | $262.8k | | 05/26/2022 |
05/25/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 90.2k | $3.18 | $286.2k | See footnotes | 05/24/2022 |
05/24/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 100k | $3.29 | $329k | See footnotes | 05/24/2022 |
05/23/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 15.6k | $3.35 | $52.2k | See footnotes | 05/19/2022 |
05/20/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 100k | $3.46 | $345.6k | See footnotes | 05/19/2022 |
05/19/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 100k | $3.49 | $348.6k | See footnotes | 05/19/2022 |
04/13/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 617.3k | $4.05 | $2.5M | See footnotes | 04/13/2022 |
04/12/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 598.1k | $4.18 | $2.5M | See footnotes | 04/12/2022 |
02/07/2022 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 1.1M | $4.42 | $5M | See footnotes | 02/07/2022 |
01/03/2022 | Mersana Therapeutics, Inc. | MRSN | Grant | Stock Option (Right to Buy) | 11k | $6.44 | $70.8k | | 01/03/2022 |
12/30/2021 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 815k | $6.15 | $5M | See footnotes | 12/30/2021 |
12/29/2021 | Mersana Therapeutics, Inc. | MRSN | Purchase | Common Stock | 875k | $5.75 | $5M | See footnotes | 12/29/2021 |
08/27/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Conversion | Common Stock | 1.9M | $0.00 | $0 | See footnotes | 08/27/2021 |
08/27/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 2M | $16.22 | $32.4M | See footnotes | 08/27/2021 |
08/27/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Conversion | Series B Convertible Preferred Stock | 1.9k | $0.00 | $0 | See footnotes | 08/27/2021 |
08/09/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Conversion | Common Stock | 2.2M | $0.00 | $0 | See footnotes | 08/09/2021 |
08/09/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Sale | Common Stock | 2.2M | $10.80 | $24.3M | See footnotes | 08/09/2021 |
08/09/2021 | DYNAVAX TECHNOLOGIES CORP | DVAX | Conversion | Series B Convertible Preferred Stock | 2.2k | $0.00 | $0 | See footnotes | 08/09/2021 |
|